ABUS
Price
$3.82Alerts
Change
+$0.10 (+2.69%)
Updated
Nov 10 closing price
Capitalization
724.08M
One day until earnings call
Intraday BUY SELL Signals
IDNA
Price
$42.53Alerts
Change
-$1.04 (-2.39%)
Updated
Nov 10 closing price
Net Assets
339.17M
Intraday BUY SELL Signals
Interact to see
Advertisement

ABUS vs IDNA

ABUS vs IDNA Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ABUS vs. IDNA commentary
Nov 11, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABUS is a Hold and IDNA is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ABUS with price predictions
Nov 10, 2026

ABUS's Indicator enters downward trend

The Aroon Indicator for ABUS entered a downward trend on November 10, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 180 similar instances where the Aroon Indicator formed such a pattern. In 151 of the 180 cases the stock moved lower. This puts the odds of a downward move at 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ABUS as a result. In 63 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.

The Moving Average Convergence Divergence Histogram (MACD) for ABUS turned negative on November 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 32 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABUS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ABUS's RSI Indicator exited the oversold zone, 23 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +4.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABUS advanced for three days, in 183 of 249 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.

ABUS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. ABUS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.799) is normal, around the industry mean (3.498). P/E Ratio (4.627) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.220) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.400) is also within normal values, averaging (440.869).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABUS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for IDNA with price predictions
Nov 10, 2026

Aroon Indicator for IDNA shows an upward move is likely

IDNA's Aroon Indicator triggered a bullish signal on November 10, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 199 similar instances where the Aroon Indicator showed a similar pattern. In 173 of the 199 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on IDNA as a result. In 76 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.

Following a +5.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where IDNA advanced for three days, in 243 of 283 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 58 cases where IDNA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 86%.

The Moving Average Convergence Divergence Histogram (MACD) for IDNA turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 46 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IDNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

IDNA broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

FUNDAMENTALS RATINGS
ABUS: Fundamental Ratings
ABUS
OUTLOOK RATING
1..100
67
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
15
PRICE GROWTH RATING
1..100
73
P/E GROWTH RATING
1..100
59
SEASONALITY SCORE
1..100
75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ABUSIDNA
RSI
ODDS (%)
Bullish Trend 1 day ago
82%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
75%
Bearish Trend 1 day ago
86%
Momentum
ODDS (%)
Bearish Trend 1 day ago
77%
Bullish Trend 1 day ago
84%
MACD
ODDS (%)
Bearish Trend 1 day ago
71%
Bearish Trend 1 day ago
88%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
76%
Bullish Trend 1 day ago
85%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
74%
Bullish Trend 1 day ago
87%
Advances
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 3 days ago
86%
Declines
ODDS (%)
Bearish Trend 6 days ago
76%
Bearish Trend 10 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
74%
Bearish Trend 1 day ago
89%
Aroon
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
87%
COMPARISON
Comparison
Nov 11, 2026
Stock price -- (ABUS: $3.82)
Brand notoriety:
Market capitalization --

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABUS’s FA Score shows that 1 FA rating(s) are green while .

  • ABUS’s FA Score: 1 green, 4 red.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABUS’s TA Score shows that 4 TA indicator(s) are bullish.

  • ABUS’s TA Score: 4 bullish, 4 bearish.

Price Growth

ABUS (@Biotechnology) experienced а -1.55% price change this weekfor the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.36%. For the same industry, the average monthly price growth was -9.96%, and the average quarterly price growth was +79.71%.

Reported Earning Dates

ABUS is expected to report earnings on Nov 12, 2026.

Industries' Descriptions

@Biotechnology (-0.36% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

ABUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABUS has been loosely correlated with RCKT. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ABUS jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABUS
1D Price
Change %
ABUS100%
+2.69%
RCKT - ABUS
45%
Loosely correlated
-3.16%
MGTX - ABUS
44%
Loosely correlated
+1.37%
PCVX - ABUS
43%
Loosely correlated
-1.73%
ARRY - ABUS
43%
Loosely correlated
-8.86%
AXON - ABUS
42%
Loosely correlated
-0.21%
More

IDNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDNA has been loosely correlated with FATE. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if IDNA jumps, then FATE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDNA
1D Price
Change %
IDNA100%
-2.39%
FATE - IDNA
57%
Loosely correlated
-8.76%
DNA - IDNA
54%
Loosely correlated
-2.91%
SANA - IDNA
51%
Loosely correlated
-1.42%
BNGO - IDNA
51%
Loosely correlated
+6.03%
ABUS - IDNA
51%
Loosely correlated
+2.69%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HTHT50.650.44
+0.88%
H World Group Limited
NRXP2.36-0.02
-0.84%
NRX Pharmaceuticals
ZLAB26.43-0.43
-1.60%
Zai Lab Limited
MGN3.40-0.09
-2.58%
Megan Holdings Limited
EVO1.69-0.05
-2.87%
Evotec SE